Literature DB >> 18184370

Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?

D Muyllaert1, A Kremer, T Jaworski, P Borghgraef, H Devijver, S Croes, I Dewachter, F Van Leuven.   

Abstract

Phosphorylation is the most common post-translational modification of cellular proteins, essential for most physiological functions. Deregulation of phosphorylation has been invoked in disease mechanisms, and the case of Alzheimer's disease (AD) is no exception: both in the amyloid pathology and in the tauopathy are kinases deeply implicated. The glycogen synthase kinase-3 (GSK-3) isozymes participate in diverse cellular processes and important signalling pathways and have been implicitly linked to diverse medical problems, i.e. from diabetes and cancer to mood disorders and schizophrenia, and in the neurodegeneration of AD. Here, we review specific aspects of GSK-3 isozymes in the framework of recent data that we obtained in novel transgenic mouse models that robustly recapitulate the pathology and mechanistical problems of AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184370     DOI: 10.1111/j.1601-183X.2007.00376.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  48 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.

Authors:  Dimitrios Kapogiannis; Mark P Mattson
Journal:  Lancet Neurol       Date:  2010-12-10       Impact factor: 44.182

Review 3.  Platelet biomarkers in Alzheimer's disease.

Authors:  Leda L Talib; Helena Pg Joaquim; Orestes V Forlenza
Journal:  World J Psychiatry       Date:  2012-12-22

4.  Neurotrophic Effect of Asiatic acid, a Triterpene of Centella asiatica Against Chronic 1-Methyl 4-Phenyl 1, 2, 3, 6-Tetrahydropyridine Hydrochloride/Probenecid Mouse Model of Parkinson's disease: The Role of MAPK, PI3K-Akt-GSK3β and mTOR Signalling Pathways.

Authors:  Jagatheesan Nataraj; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa
Journal:  Neurochem Res       Date:  2017-02-08       Impact factor: 3.996

5.  Possible association of the GSK3β gene with the anxiety symptoms of major depressive disorder and P300 waveform.

Authors:  Sha Liu; Ning Sun; Yong Xu; Chunxia Yang; Yan Ren; Zhifen Liu; Xiaohua Cao; Yan Sun; Qi Xu; Kerang Zhang; Yan Shen
Journal:  Genet Test Mol Biomarkers       Date:  2012-10-02

6.  Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.

Authors:  Konstantina Vougogiannopoulou; Yoan Ferandin; Karima Bettayeb; Vassilios Myrianthopoulos; Olivier Lozach; Yunzhen Fan; Carl Hirschie Johnson; Prokopios Magiatis; Alexios-Leandros Skaltsounis; Emmanuel Mikros; Laurent Meijer
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

7.  [Alzheimer's disease. Molecular pathology, animal models, and current treatment].

Authors:  T A Bayer; O Wirths
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

8.  Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease.

Authors:  Tomasz Jaworski; Sebastian Kügler; Fred Van Leuven
Journal:  Int J Alzheimers Dis       Date:  2010-08-24

9.  Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.

Authors:  Oyinkan Sofola; Fiona Kerr; Iain Rogers; Richard Killick; Hrvoje Augustin; Carina Gandy; Marcus J Allen; John Hardy; Simon Lovestone; Linda Partridge
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

10.  Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons.

Authors:  Agnès Petit-Paitel; Frédéric Brau; Julie Cazareth; Joëlle Chabry
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.